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Abstract
The FMR1 gene partially appears to control ovarian reserve, with a specific ovarian sub-genotype statistically associated with
a polycystic ovary (PCO)- like phenotype. Some forms of PCO have been associated with autoimmunity. We, therefore,
investigated in multiple regression analyses associations of ovary-specific FMR1 genotypes with autoimmunity and
pregnancy chances (with in vitro fertilization, IVF) in 339 consecutive infertile women (455 IVF cycles), 75 with PCO-like
phenotype, adjusted for age, race/ethnicity, medication dosage and number of oocytes retrieved. Patients included 183
(54.0%) with normal (norm) and 156 (46%) with heterozygous (het) FMR1 genotypes; 133 (39.2%) demonstrated laboratory
evidence of autoimmunity: 51.1% of het-norm/low, 38.3% of norm and 24.2% het-norm/high genotype and sub-genotypes
demonstrated autoimmunity (p=0.003). Prevalence of autoimmunity increased further in PCO-like phenotype patients with
het-norm/low genotype (83.3%), remained unchanged with norm (34.0%) and decreased in het-norm/high women (10.0%;
P,0.0001). Pregnancy rates were significantly higher with norm (38.6%) than het-norm/low (22.2%, p=0.001). FMR1 sub-
genotype het-norm/low is strongly associated with autoimmunity and decreased pregnancy chances in IVF, reaffirming the
importance of the distal long arm of the X chromosome (FMR1 maps at Xq27.3) for autoimmunity, ovarian function and,
likely, pregnancy chance with IVF.
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Introduction
Recent publications reported associations between number of
triple CGG nucleotide repeats on the fragile X mental retardation 1
(FMR1) gene and risk towards premature ovarian senescence [1–8],
leading in milder cases to so-called premature ovarian aging (POA)
[2,9], also called occult primary ovarian insufficiency (OPOI) [10],
and at end stage to premature ovarian failure (POF), also called
primary ovarian insufficiency (POI) [10]. We recently reported
evidence that different FMR1 genotypes vary in rate of follicle
recruitment and, therefore, at least partially, affect functional
ovarian reserve, as assessed by anti-Mu ¨llerian hormone (AMH) [8].
A normal triple nucleotide (CGG) count range of 26 to 34
repeats (median 30), in respect to ovarian function, allows
definition of distinct FMR1 genotypes, depending on whether
both (normal), only one (heterozygous) or neither (homozygous) allele is
in normal range [8,11]. In a small pilot study a heterozygous-normal/
low (het-norm/low) sub-genotype appeared associated with a lean
polycystic ovary (PCO)-like phenotype with rapidly depleting
ovarian reserve [12].
A PCO-like phenotype is integral to all definitions of the
polycystic ovary syndrome (PCOS) [13]. The phenotype, however,
solely denotes excessive follicle activity (reflected in high AMH)
and, consequently, hyperactivity of ovarian function. PCO and
PCOS, therefore, have distinctively different connotations.
Some authors have speculated about a possible autoimmune
etiology for selected forms of PCOS [14–16]. Others implied such
an association when histological demonstrating autoimmune
oophoritis with polycystic aspects, accompanied by anti-ovarian
antibodies [17–19].
At the other end of ovarian function, autoimmunity has been for
decades implicated in POF/POI [20]. A very specific phenotype,
characterized by a preserved pool of functional follicles, has
recently been associated with steroidogenic cell autoimmunity
[21]. Hypo-activity is, thus, well documented in association with
autoimmunity, while hyperactivity of ovaries is not.
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associated suppression of ovarian function, we have speculated
about autoimmune-induced ovarian stimulation in PCOS patients
[22], which would mimic the independent duality of, for example,
thyroid autoimmunity and function, both etiologically linked,
interacting, yet relatively independent of each other [23].
Initial efforts at our center to demonstrate evidence for
autoimmune activity in association with PCOS remained unsuccess-
ful (Weghofer A, Gleicher N, unpublished data). We attributed our
failure to phenotypical and etiologic variabilities of PCOS, as defined
by current Rotterdamcriteria[13]. Identifyingabove noted PCO-like
phenotype with close association to the het-norm/low FMR1 sub-
genotype offered, however, a unique opportunity to study a clinically
homogenous PCO-like patient population. While widely suspected,
close genetic markers of PCOS are still lacking [24].
This study confirms close associations between FMR1 genotypes
and ovarian function but for the first time also associates FMR1
genotypes in infertile women with risk towards autoimmunity and
with pregnancy chances in association with in vitro fertilization
(IVF).
Methods
This study involved the retrospective review of medical records.
All data utilized were extracted from medical charts and the
Center’s centralized, confidential electronic research data bank.
Patients, at time of initial consultation, sign an informed consent,
which permits such utilization of medical records for research
purposes as long as the patients’ identities remain undisclosed,
medical records are untraceable and remain confidential. The
Center’s Institutional Review Board (IRB) allows such studies
under expedited review.
Patients/cycles
We investigated 339 consecutive female infertility patients who
presented to our center for initial diagnostic evaluation, which
routinely includes limited genetic and immunologic testing.
Amongst those, 75 women qualified as PCO-like phenotypes, based
on largenumbers ofoocytesretrieved($12)infirst IVF cycles,and/
or high anti-Mu ¨llerian hormone (AMH, .4.0 ng/mL) at initial
evaluations. These cut offvalueswerechosen in consideration of the
high prevalence of diminished ovarian reserve in our patient
population [9] (see also ovarian reserve tests in Table 1).
The 339 patients underwent 455 IVF cycles, 116 thus
representing repeat attempts. As Appendix S1, however, demon-
strates, adding a covariate for number of IVF cycles experienced
by each patient does in our patient population not affect the
findings of an analysis based on per patient outcomes.
Genetic testing includes an assessment of triple CGG nucleotide
repeats on the FMR1 gene, as reported before [5–8]. We
previously also reported that, in regards to ovarian function, 26
to 34 repeats represent a normal range (median 30) [8], and counts
below and above denote risk towards POA/OPOI [6]. Based on
this normal range, normal (norm), heterozygous (het) and homozygous
(hom) FMR1 genotypes can be described, which are reflective of
distinct ovarian aging patterns [8]. They are defined by both
alleles in normal range (norm), either one outside of range (het)o r
both alleles outside of range (hom). A het patient, in turn, can be
either het-norm/low (,26 repeats) or het-norm/high (.34 repeats),
while hom patients may be either high/high, high/low or low/low.
The het-norm/low FMR1 genotype has in a longitudinal and
cross-sectional study been associated with very high ovarian
reserve (based on AMH) at young ages, which, however, in the
early 30 s, quickly depletes, resulting in rapid AMH declines at
relatively young ages and relatively diminished age-dependent
ovarian reserve thereafter [12]. Women with this genotype after
ages 32–33 years, therefore, lose their PCO-like phenotype and,
without FMR1 evaluations, based on AMH levels alone, would be
perceived as either normal or suffering from prematurely
diminished ovarian reserve.
Immunological testing involves, as previously reported [25],
total immunoglobulin levels (IgG, IgM, IgA), antinuclear, anti-
phospholipid and anti-thyroid antibody panels, as well as anti-
ovarian and anti-adrenal antibodies. We previously demonstrated
that this panel of immunological tests is sufficient in identifying
even subclinical levels of autoimmunity that predisposes towards
POA/OPOI [25,26]. In utilizing this established screening
method, a patient was defined as autoimmune-negative with
absence of any abnormality and was considered autoimmune-
positive with presence of even one, fully recognizing that such a
definition increases sensitivity at expense of specificity and,
therefore, weakens the discovery of potentially existing associations
with autoimmunity. This definition of autoimmunity, therefore,
consciously biases results against positive association and, thus,
strengthens any detected associations.
IVF cycles were conducted in routine fashion. In principle, only
two ovarian stimulation protocols were utilized: women with
normal ovarian reserve were down-regulated with a gonadotropin
releasing hormone agonist and stimulated with maximally 300 IU
of gonadotropins daily. Patients with diminished ovarian reserve
received a micro-dose agonist protocol with 450 to 600 IU of
gonadotropins daily. Hormone assays for follicle stimulating
hormone (FSH), estradiol and AMH were run in house as
previously reported [27].
Table 1. Patient characteristics
*.
Ovarian Phenotype
Normal PCO-like P-Value
Number 264 75
Age (years) 38.864.8 34.864.3 ,0.0001
FSH (mIU/MI, 95% CI) 10.3 (9.72–11.03) 7.35 (6.67–8.08) ,0.0001
AMH (ng/mL, 95% CI) 0.55 (0.48–0.62) 2.21 (1.76–2.77) ,0.0001
BMI 22.7613.5 23.3613.2 0.74 (N.S.)
Oocytes retrieved (n) 4.863.3 17.566.7 ,0.0001
Embryos transferred (n) 2.461.1 2.460.8 0.88 (N.S.)
Ethnicity/Race (n/%)
Caucasian 157 (59.5) 43 (57.3)
African 33 (12.5) 12 (16.0)
Asian 38 (14.4) 10 (13.3)
Middle Eastern 11 (4.2) 2 (2.7)
Ashkenazi Jewish 15 (5.7) 6 (8.0)
Other 10 (3.8) 2 (2.7)
Autoimmunity (n/%)
No 162 (61.4) 43 (57.3) N.S.
Yes 102 (38.6) 32 (46.7)
*Ovarian reserve tests in this table reflect first patient evaluations. IVF outcome
data reflect only first IVF cycles.
Data are shown with confidence intervals when log-transformed for analysis
and with standard deviations where not. Positive autoimmunity denotes sum of
all positive patients, demonstrating at least one abnormality in the immune
panel tested (for further details, see Methods section).
doi:10.1371/journal.pone.0015303.t001
FMR1 Genotype with PCO and Low Pregnancy Chance
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15303Statistical Analysis
Patient characteristics and IVF cycle outcomes were evaluated in
association with FMR1 genotypes and autoimmune status, as
defined above. PCO-like phenotypes were distributed in 62 percent
as norm, 25 percent as het-norm/low and 13 percent as het-norm/high
and represented 22 percent of all patients. Women with normal
ovarian phenotype were in same order distributed at 52, 28 and 20
percent, respectively and represented 78 percent of all patients.
This distribution corresponds to an effect size, w, of 0.091 and,
equivalently, to a contingency coefficient (C) as well as a Cramer’s
phi coefficient (phi) of 0.091. With a sample size of 339 the study,
thus, had only a power of 30.3% to yield statistically significant
results. Assuming continuation of in this study observed propor-
tions, a study with identical effect size (w=0.091) would require a
sample size of 1,164 patients to achieve an 80 percent power to
detect a significant alpha (0.05, two-tailed).
Univariate comparison between women with PCO-like pheno-
type and control was performed using Chi Square and analysis of
variance as appropriate. Variables in which the distribution of data
did not conform to normality were first log transformed for analysis
and then converted back to standard units for presentation. Where
cycles served as study units, odds ratios were compared. Continuous
variables are presented as either mean 6 standard deviation (SD) or
mean and 95 percent confidence interval (95% CI), as appropriate.
We constructed a general linear model with logit link function,
testing the association of the PCO-like phenotype with FMR1, and
autoimmunity and also for pregnancy. General linear models were
run on SAS version 9.2 (GENMOD module).
Results
Table 1 summarizes patient characteristics for all 339 women,
amongst those 264 (77.9%) representing a normal, non-PCO-like
ovarian phenotype and 75 (22.1%) the defined PCO-like phenotype.
Women with PCO were younger (34.864.3 vs. 38.864.8 years,
P,0.0001), had lower FSH (8.064.0 vs. 11.966.8 mIU/mL, P,
0.0001) and higher AMH levels (3.262.6 vs. 0.860.7 ng/mL
P,0.0001) and produced larger oocyte yields (17.565.6 vs. 4.86
3.3, P,0.0001).Otherwise, the two groups did not differ significantly,
including in ethnic/racial distribution and BMI, confirming the non-
obese nature of the here investigated PCO-like phenotype.
FMR1 Genotypes
Table 2 summarizes FMR1 genotype distribution patterns in
women with apparently normal and PCO-like ovaries. Amongst
264 women with normal ovaries 137(51.9%) demonstrated a norm
FMR1 genotype; the remaining 127 (48.1%) were het (there were
no hom patients in the study population), 52 (19.7%) were het-norm/
high and 75 (28.4%) het-norm/low. This distribution did not
significantly differ from the FMR1 genotype distribution amongst
the 75 women with PCO-like phenotype, where norm were 46
(61.3%), het-norm/high 10 (13.3%) and het-norm/low 19 (25.3%). The
previously noted age-dependency of the definition of the PCO-like
phenotype [12] mandates caution in interpreting these results.
Autoimmunity
Distribution of autoimmunity also did not differ between both
patient groups (Table 1): In women with normal ovaries 162/264
(61.4%) showed no evidence of autoimmunity and 102 (38.6%) did,
whileinthe PCO-likecohort43(57.3%)didnot and32(46.7%)did.
If autoimmunity was, however, assessed in reference to FMR1
genotype (Figure 1), the het-norm/low genotype was most frequently
associated with autoimmunity (51.1%), followed by norm patients
(38.3%) and het-norm/high women (24.2%), a statistically significant
difference in distribution (p=0.003). These differences in distribution
further strengthened in women with PCO-like phenotype: het-norm/low
women demonstrated autoimmunity in 83.3 percent of cases, while het-
norm/high genotypes in only 10.0 percent, almost categorically
differentiating between these two het genotypes, while norm women
held a middle ground with 34.0 percent prevalence (P,0.0001).
IVF Pregnancy Rates
Pregnancy outcomes in 455 consecutive IVF cycles are
summarized in Figure 2. As the figure demonstrates, norm women
experienced the highest pregnancy rates (38.6%), a rate significantly
higher than in het-norm/low patients [22.2%; OR 0.84 (95% CI 0.74
to 0.96; Wald 6.9; df=1; P=0.009)]. Women with het-norm/high
genotype had intermediate pregnancy rates at 31.7 percent.
Adjustment for age maintained the disadvantage in pregnancy rate
for het-norm/low women (OR 0.43; 0.22 to 0.86, p=0.017).
Discussion
This study demonstrates that in consecutive patients presenting
for infertility treatments the prevalence of autoimmunity varies
significantly with FMR1 genotype, with het-norm/low presenting
with most and het-norm/high with least autoimmunity. This
Table 2. FMR1 genotype distribution
*.
Phenotype Norm Het-Norm/High Het-Norm/Low
PCO-like 46 (61.3) 10 (13.3) 19 (25.3)
Normal 137 (51.9) 52 (19.7) 75 (28.4)
Total 183 (54.0) 62 (18.3) 94 (27.7)
*Chi-Square 2.46, df =2.0, P=0.29.
doi:10.1371/journal.pone.0015303.t002
Figure 1. Prevalence of autoimmunity in reference to FMR1
genotype. The prevalence of autoimmunity was in both patient
groups the highest with het-norm/low FMR1 genotype and the lowest
with het-norm/high genotype. This pattern, however, intensified in
women with PCO-like phenotype. Gray bars represent women with
normal ovarian reserve; white bars represent the PCO-like phenotype.
doi:10.1371/journal.pone.0015303.g001
FMR1 Genotype with PCO and Low Pregnancy Chance
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lean PCO-like phenotype, we previously described in a pilot study
associated with the het-norm/low FMR1 genotype and with
relatively rapidly depleting ovarian reserve [12]. Such patients
almost guarantee positive autoimmune laboratory findings (83.3%
prevalence, Figure 1), while a het-norm/high genotype is practically
protective against autoimmunity (10.0% prevalence). Women with
norm FMR1 genotype in both patient populations take up a middle
ground with 38.3% and 34.0% prevalence, respectively.
The close association between the het-norm/low genotype and
autoimmunity is further supported by the fact that the PCO-like
phenotype was significantly younger (P ,0.0001, Table 1), while
autoimmunity actually increases in prevalence with advancing
female age [28]. PCO-like phenotypes, thus, demonstrated
significantly more autoimmunity, despite significantly younger ages.
The statistical clarity of here reported results is, however,
especially remarkable, considering that patient selection criteria in
this study strongly biased against discovery of such statistical
associations. As already previously noted, the definition of positive
autoimmunity consciously was based on improving sensitivity at
the expense of specificity. Women defined as autoimmune,
therefore, likely included a few without real polyclonal autoim-
mune activation.
Even more significantly, however, we noted earlier the time line
for premature declines in ovarian reserve in women with the het-
norm/low FMR1 genotype [12]. Even though the here investigated
group of patients with PCO-like phenotype were significantly
younger (P,0.0001, Table 1), it appears likely that older women
with apparently normal ovarian phenotype must include at least
some who at younger ages actually did demonstrate a PCO-like
phenotypes.
Patients with PCO-like phenotype, in this study defined by 12 or
more oocytes retrieved and/or an AMH above 4.0 ng/mL,
represented 75 (22.1%) of all patients investigated. The definition
of the PCO-like phenotype in this study was purely clinical, meant
to identify a patient population with disproportionally high
ovarian reserve, as documented by high oocyte yields and AMH
values. Considering that the here investigated patient population
included, as also previously reported [9], a disproportionate
number of women with significantly diminished ovarian reserve
(confirmed by elevated FSH, low AMH and oocyte yields in
women with normal ovarian phenotype, Table 1), here chosen cut
offs, defining a PCO-like phenotype for study purposes, appear
appropriate. Twelve or more oocytes in such patients are above
expected averages, as even women under age 35 years at our
center produce only an average of 8.265.8 oocytes [29]. Similarly,
an AMH above 4.0 ng/mL exceeds the 95% confidence interval
(CI) of AMH levels at our center in women as young as age 26
years [30].
Here reported autoimmune laboratory findings in slightly above
one third of women correspond well to prevalence numbers for
infertility populations, reported in the literature [31,32]. This not
only validates the selected study population but also reaffirms the
immune profile used in this, and prior studies [25,26], to define
presence of subclinical levels of autoimmunity. Though not
reaching significance, prevalence of autoimmunity further in-
creased (38.6% to 46.7%) from normal ovarian to PCO-like
phenotypes. As further discussed below, this finding appears
primarily the consequence of the strong association between het-
norm/low FMR1 genotype and autoimmunity.
To define autoimmunity at subclinical levels is difficult to
impossible, and is the reason why clinical diagnoses of autoim-
mune conditions in prodromal stages often are difficult [28].
Autoimmunity is, however, typically associated with a polyclonal
activation of the immune system, which can be detected by
broadly based laboratory evaluations [33,34]. While such screens
are not specific enough for diagnoses of autoimmune diseases, they
appear sensitive enough in defining evidence of autoimmune
activity [25,26].
This study, once again, reaffirms this by demonstrating a
surprisingly close association between autoimmunity and the het-
norm/low FMR1 genotype. We already previously associated the
het-norm/low genotype in a pilot study with a PCO-like phenotype,
with rapidly depleting ovarian reserve [12]. Women with this
genotype present at young ages with a PCO phenotype. Because of
rapid follicle depletion (i.e., rapidly diminishing ovarian reserve),
they then at older ages demonstrate normal to abnormally low
AMH levels, reflecting relative or outright diminished ovarian
reserve.
Since the FMR1 gene appears closely involved with regulation
of follicle recruitment and, therefore, ovarian reserve [1–8], the
association between het-norm/low FMR1 genotype and PCO-like
phenotype does not surprise. The extremely close association
between het-norm/low genotype and autoimmunity was, however,
completely unanticipated. This association appears, indeed, so
close that in a PCO-like population a het-norm/low genotype
virtually predicts autoimmunity, while women with the het-norm/
high genotype appear protected from autoimmunity.
These associations also translate into clinical significance for
infertile women since the FMR1 genotype appears predictive of
pregnancy chances with IVF. Women experience best pregnancy
chances with norm, intermediate with het-norm/high and lowest rates
with het-norm/low genotypes (Figure 2).
Whether a PCO-like phenotype, alone, affects pregnancy
chances in IVF has remained controversial [35]. Lower [36] and
similar [37] pregnancy rates have been suggested in PCOS in
comparison to other infertile patients undergoing IVF. Multiple
underlying etiologies for PCOS [13], different ovarian stimulation
protocols and variability in genetic definitions of study populations
easily explain such discrepancies.
The same kind of controversy surrounds the association of
autoimmunity and pregnancy success in IVF. Many authorities
Figure 2. Pregnancy rates in IVF based on FMR1 genotype.
Pregnancy rates were the highest with norm FMR1 genotype and the
lowest with het-norm/low genotype.
doi:10.1371/journal.pone.0015303.g002
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have pointed at considerable evidence [41,42]. Here presented
data suggest a possible explanation for these contradictory
opinions since, like PCOS, most studies on autoimmunity have
been performed in genetically and etiologically heterogenic patient
populations. At least in a genetically homogenous population of
women with the het-norm/low FMR1 genotype, autoimmunity,
indeed, appears negatively associated with pregnancy chances in
IVF.
Autoimmunity is abnormally high in practically all X-linked
disorders [43]. If defective, a MHC-paralogue on the long arm of
the X chromosome renders individuals immunologically less
efficient [44]. With the FMR1 gene mapping to Xq27.3 [45], it
appears to occupy the cross roads between ovarian function
(ovarian recruitment and ovarian reserve) and autoimmunity
[43,44,46].
Both autoimmunity and abnormalities in ovarian reserve are
closely associated with X chromosome defects: A good example is
Turner syndrome, in which Xq21 terminal deletions are common,
often large and characterized by primary as well as secondary
amenorrhea [46,47]. Xq21 or further distal deletions usually
present with secondary amenorrhea [47], a classical clinical
presentation of premutation range FMR1 (fragile X) carriers who
present with POF/POI [10,48]. In contrast Turner syndrome with
normal fertility generally involves more proximal Xq deletions
[49].
POF/POI, indeed, demonstrates a 4MB locus exactly at Xq27-
q28 [46], with the FMR1 gene mapping to Xq27.3 [45]. Small
deletions in Xq27-q28 have variable phenotypes, some with early
menopause but are usually able to reproduce until experiencing
full POF/POI [46]. Similar correlations with ovarian function are
also observed in balanced translocations, where only Xq23-q27
deletions are associated with POF/POI [46].
Turner syndrome is not only characterized by above noted
abnormalities in ovarian function but, like most X-linked
disorders, also by excessive autoimmunity. Both autoantibodies
and autoimmune diseases are significantly increased [44]. The
close association between X-linked disorders and autoimmunity
led to the suggestion that the latter may be the consequence of
genes and/or mutations on the long arm of the X chromosome
[43], potentially explaining the increased prevalence of autoim-
munity in women in comparison to males [50].
A PCO-like phenotype with strongly associated autoimmunity
and specific FMR1 genotype (het-norm/low), and the protective
effect of another FMR1 genotype (het-norm/high), support the
notion we made earlier [8] that the FMR1 gene plays a role
in regulating ovarian reserve. Now it appears that the same gene
may also be involved in determining risk/protection of/from
autoimmunity.
These observations also raise the intriguing possibility that a
PCO-like phenotype may be associated with an autoimmune
etiology. This has previously been suggested [14–19,22] but, in
contrast to cases of POF/POI [20,21], PCO and/or PCOS have
never been established as autoimmune in nature. Like POF/POI
in its various forms [10,25,26,51], PCOS is multifactorial in
etiology [13], with PCO being a unifying phenotypical presenta-
tion of an, otherwise, still very controversial syndrome [52].
Only very recently, Hefter Frischmuth and associates reported
serological evidence for elevated autoimmunity in women with
PCOS [16]. The authors, like also in this study, investigated non-
organ specific (antihistone and anti-dsDNA) antibodies. Another
Austrian group, however, even more recently, reported a statistical
association between levels of anti-thyroid peroxidase antibodies
and treatment response in women with PCOS, suggesting that
organ specific thyroid antibodies may also be associated with
PCOS [53]. Thyroid autoimmunity, of course, is well known to be
closely associated with ovarian autoimmunity [20].
These reports and here presented data support the hypothesis
that, like other endocrine organs, ovaries may be subject to
suppressive and stimulatory autoimmune influences, possibly
mediated by autoantibodies, a hypothesis we previously proposed
after Baroni and associates reported stimulatory antibodies (to
platelet derived growth factor) in systemic sclerosis [54]. Building
on their findings, we speculated that ‘‘functional’’ autoantibodies
may represent a universal paradigm of autoimmunity [22].
In regards to ovarian function such a concept would suggest
inhibitory autoantibodies as cause of selected cases of POA/
OCPOI and POF/POI, as recently suggested by La Marca and
associates [21], and stimulatory autoantibodies as promoters of
follicular activity, resulting in at least one PCO-like phenotype.
Here reported strong positive and negative associations with both
het-FMR1 genotypes further suggest a possible role of the FMR1
gene in regulation of these ‘‘functional’’ autoantibodies and,
therefore, possibly, in contributing to the well established higher
prevalence of autoimmunity in females in comparison to males
[42].
Despite the substantial size of the here reported population of
infertile women, this study’s principal weakness lies in its relatively
limited power. As, however, previously noted, to achieve 80
percent power for a significant alpha under observe proportions,
close to 1,200 patients would be required. While we are continuing
to accumulate patients, this is a difficult goal to obtain in a single
center study.
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